IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v548y2017i7666d10.1038_nature23291.html
   My bibliography  Save this article

Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS

Author

Listed:
  • Zhan Yao

    (Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center)

  • Rona Yaeger

    (Memorial Sloan Kettering Cancer Center)

  • Vanessa S. Rodrik-Outmezguine

    (Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center)

  • Anthony Tao

    (Center for Neural Science, College of Arts and Sciences, New York University)

  • Neilawattie M. Torres

    (Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center)

  • Matthew T. Chang

    (Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center
    University of California, San Francisco)

  • Matthias Drosten

    (Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO))

  • Huiyong Zhao

    (Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center)

  • Fabiola Cecchi

    (Molecular Oncology Group, NantOmics, LLC, 9600 Medical Center Drive)

  • Todd Hembrough

    (Molecular Oncology Group, NantOmics, LLC, 9600 Medical Center Drive)

  • Judith Michels

    (Gustave Roussy Cancer Campus
    Faculté de médecine, Université Paris Sud)

  • Hervé Baumert

    (Saint Joseph Hospital)

  • Linde Miles

    (Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center
    Anti-Cancer Drug Development Graduate Training Program, Johns Hopkins University)

  • Naomi M. Campbell

    (Memorial Sloan Kettering Cancer Center)

  • Elisa de Stanchina

    (Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center)

  • David B. Solit

    (Memorial Sloan Kettering Cancer Center
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
    Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center)

  • Mariano Barbacid

    (Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO))

  • Barry S. Taylor

    (Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center
    Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center)

  • Neal Rosen

    (Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center
    Center for Mechanism-Based Therapeutics, Memorial Sloan Kettering Cancer Center)

Abstract

Hypoactive BRAF mutants bind more tightly than wild type to the upstream regulator RAS, thus amplifying to amplify ERK signalling; tumours expressing these mutants require coexistent mechanisms for RAS activation to grow and are sensitive to their inhibition.

Suggested Citation

  • Zhan Yao & Rona Yaeger & Vanessa S. Rodrik-Outmezguine & Anthony Tao & Neilawattie M. Torres & Matthew T. Chang & Matthias Drosten & Huiyong Zhao & Fabiola Cecchi & Todd Hembrough & Judith Michels & H, 2017. "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS," Nature, Nature, vol. 548(7666), pages 234-238, August.
    • Handle: RePEc:nat:nature:v:548:y:2017:i:7666:d:10.1038_nature23291
    DOI: 10.1038/nature23291
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/nature23291
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1038/nature23291?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Josh N. Vo & Yi-Mi Wu & Jeanmarie Mishler & Sarah Hall & Rahul Mannan & Lisha Wang & Yu Ning & Jin Zhou & Alexander C. Hopkins & James C. Estill & Wallace K. B. Chan & Jennifer Yesil & Xuhong Cao & Ar, 2022. "The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma," Nature Communications, Nature, vol. 13(1), pages 1-13, December.
    2. Tripti Shrestha Bhattarai & Tambudzai Shamu & Alexander N. Gorelick & Matthew T. Chang & Debyani Chakravarty & Elena I. Gavrila & Mark T. A. Donoghue & JianJong Gao & Swati Patel & Sizhi Paul Gao & Ma, 2022. "AKT mutant allele-specific activation dictates pharmacologic sensitivities," Nature Communications, Nature, vol. 13(1), pages 1-11, December.
    3. Gaurav Mendiratta & Eugene Ke & Meraj Aziz & David Liarakos & Melinda Tong & Edward C. Stites, 2021. "Cancer gene mutation frequencies for the U.S. population," Nature Communications, Nature, vol. 12(1), pages 1-11, December.
    4. Ezra Y. Rosen & Helen H. Won & Youyun Zheng & Emiliano Cocco & Duygu Selcuklu & Yixiao Gong & Noah D. Friedman & Ino Bruijn & Onur Sumer & Craig M. Bielski & Casey Savin & Caitlin Bourque & Christina , 2022. "The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers," Nature Communications, Nature, vol. 13(1), pages 1-9, December.
    5. Maximilian Merz & Almuth Maria Anni Merz & Jie Wang & Lei Wei & Qiang Hu & Nicholas Hutson & Cherie Rondeau & Kimberly Celotto & Ahmed Belal & Ronald Alberico & AnneMarie W. Block & Hemn Mohammadpour , 2022. "Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma," Nature Communications, Nature, vol. 13(1), pages 1-15, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:548:y:2017:i:7666:d:10.1038_nature23291. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.